BioSpace News Archive

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will present at the 33rd Annual Virtual ROTH Conference, being held on March 15-17, 2021

Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection Kit expands Agilent’s product portfolio aimed at COVID-19 detection

Corindus, A Siemens Healthineers Company and one of the leading developers of precision vascular robotics, announced it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2021, earning the No. 5 spot in the robotics category.

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present at the Oppenheimer 31 st Annual Virtual Healthcare Conference on Tuesday, March 16 th , 2021 at 9:20 a.m. ET.

Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors.

10x Genomics, Inc. announced expansion plans to support the company’s continued growth in Pleasanton across two properties.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2020 financial results and provide a corporate update on Tuesday, March 16, 2021.

Selexis SA and Boston Immune Technologies and Therapeutics (BITT) have entered into a service agreement to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and infectious diseases.

No royalty payments due for 36 months Company has started to identify key opinion leader physicians in the US as well as Europe focused on addressing the symptoms - including gastrointestinal distress - that afflict a significant proportion of COVID-19 survivors for an extended period after recovery SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today announced that the Company has signed the definitive

Sorrento Therapeutics, Inc. announced major progress in the development of COVISHIELD through the license of intellectual property developed by the scientific team at the Icahn School of Medicine at Mount Sinai.